Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | CASP4 | P49662 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP9 | P55211 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6319581 | 1.00 | CASP1 (0.39) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL6320050 | 0.84 | MAPT (0.40) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL6320047 | 0.84 | MAPT (0.40) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL6316788 | 0.84 | IDO1 (0.35) | MEN1KMT2AIDO1ALDH1A1POLB | |
| SCHEMBL6316786 | 0.84 | IDO1 (0.35) | MEN1KMT2AIDO1ALDH1A1POLB | |
| SCHEMBL6318568 | 0.83 | CASP1 (0.36) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL6318570 | 0.83 | CASP1 (0.36) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL6316609 | 0.81 | MAPT (0.40) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL6316612 | 0.81 | MAPT (0.40) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL8027844 | 0.79 | CASP1 (0.56) | CASP1CASP3CASP4CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | claimed |
| WO-2004039409-A2 | COMPOSITION COMPRISING ACTIVATORS OF IK POTASSIUM CHANNELS AND CALCINEURIN ANTAGONISTS AND USE THEREOF | SWITCH BIOTECH AG (DE) | 2004-05-13 | — | — | WO | claimed |
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S | 2003-06-19 | — | — | US | claimed |
| JP-2002531498-A | — | — | 2002-09-24 | — | — | JP | claimed |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2002-02-07 | — | — | US | claimed |
| EP-1135123-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000033834-A1 | USE OF ISATIN DERIVATIVES AS ION CHANNEL ACTIVATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-15 | — | — | WO | claimed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | claimed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | claimed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | claimed |
| JP-3204856-A | — | — | None | — | — | JP | disclosed |
| US-20050282982-A1 | Amido complexes of vanadium for olefin polymerization | LANXESS DEUTSCHLAND GMBH (DE) | 2005-12-22 | — | — | US | disclosed |
| US-6969729-B2 | Use of isatin derivatives as ion channel activating agents | NEUROSEARCH A/S (DK) | 2005-11-29 | — | — | US | disclosed |
| EP-1345618-B1 | CHLORZOXAZONE FOR THE TREATMENT OF PSORIASIS | SWITCH BIOTECH AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| US-20040248099-A1 | Use of intermediate -conductance potassium channels and modulators for diagnosing and treating diseases having disturbed keratinocyte activity | SWITCH BIOTECH AKTIENGESELLSCHAFT (DE) | 2004-12-09 | — | — | US | disclosed |
| EP-0432648-B1 | Isatine derivatives, their preparation and use | NEUROSEARCH AS (DK) | 1995-08-02 | — | — | EP | disclosed |
| US-5198461-A | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| US-5192792-A | Isatine derivatives, and their method of use | WARNER-LAMBERT COMPANY (US) | 1993-03-09 | — | — | US | disclosed |
| JP-H03204856-A | ISATINE DERIVATIVES, PREPARATION AND USE PROCESS THEREOF | NEUROSEARCH AS | 1991-09-06 | — | — | JP | disclosed |
| EP-0432648-A2 | Isatine derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114513-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CASP1 2814/4885CASP3 3446/4885CASP4 4043/4885 |
| US-20050282982-A1 | Amido complexes of vanadium for olefin polymerization | NOX4, NOXO1, COG4 | CASP1 4704/4885CASP3 2059/4885CASP4 1635/4885 |
| US-20020016354-A1 | Use of isatin derivatives as ion channel activating agents | KCNN3, KCNJ2, KCND2 | CASP1 2586/4885CASP3 3296/4885CASP4 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.